Announced Tue, 29 Sept, 2026 · 15:35 IST

41st AGM voting results - all 4 resolutions passed with near-unanimous support

Board & Shareholder Meetings View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹22.45

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+5.3% vs market

Pharmaceuticals peers, median of 172sector-0.9%+5.9% vs sector

On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 5.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0-0.3+5.3-0.9+5.9

Next day

+9.6-1.5+11.1-1.7+11.2

+9.1-1.5+10.7-2.6+11.7

+14.4-0.2+14.7-1.5+15.9

+13.6-0.5+14.1-1.8+15.4

+13.1-3.2+16.4-3.5+16.6

+9.1-2.2+11.3-4.4+13.5

15d

—-9.5—-9.2—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Brawn Biotech held its 41st AGM on 29 Sep 2026 via video conferencing. All 4 ordinary resolutions passed with around 99.99% approval: adoption of FY26 audited financials, re-appointment of Mr. Brij Raj Gupta as director (retiring by rotation), appointment of M/s GDSM and Co as statutory auditors, and approval of managerial remuneration for Mr. Amit Kumar (Manager-KMP). Out of 3,271 shareholders on the cut-off date, 44 attended via VC and 89 cast votes through remote e-voting.

Likely market impact

Routine procedural approvals with near-unanimous shareholder support. No material impact on stock price expected.